205 related articles for article (PubMed ID: 16918414)
1. Adhesion dependent signalling in the tumour microenvironment: the future of drug targetting.
Bewick MA; Lafrenie RM
Curr Pharm Des; 2006; 12(22):2833-48. PubMed ID: 16918414
[TBL] [Abstract][Full Text] [Related]
2. Cell adhesion and cancer: is there a potential for therapeutic intervention?
Lafrenie RM; Buckner CA; Bewick MA
Expert Opin Ther Targets; 2007 Jun; 11(6):727-31. PubMed ID: 17504010
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.
Alimbetov D; Askarova S; Umbayev B; Davis T; Kipling D
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882812
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance in cancer therapy: role of the microenvironment.
Galmarini CM; Galmarini FC
Curr Opin Investig Drugs; 2003 Dec; 4(12):1416-21. PubMed ID: 14763126
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms for tumour resistance to chemotherapy.
Pan ST; Li ZL; He ZX; Qiu JX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):723-37. PubMed ID: 27097837
[TBL] [Abstract][Full Text] [Related]
6. Adhesion molecules as targets for the treatment of neoplastic diseases.
Syrigos KN; Karayiannakis AJ
Curr Pharm Des; 2006; 12(22):2849-61. PubMed ID: 16918415
[TBL] [Abstract][Full Text] [Related]
7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
8. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling.
Hagland H; Nikolaisen J; Hodneland LI; Gjertsen BT; Bruserud Ø; Tronstad KJ
Expert Opin Ther Targets; 2007 Aug; 11(8):1055-69. PubMed ID: 17665978
[TBL] [Abstract][Full Text] [Related]
9. Targeting apoptosis pathways in cancer therapy.
Fulda S; Debatin KM
Curr Cancer Drug Targets; 2004 Nov; 4(7):569-76. PubMed ID: 15578914
[TBL] [Abstract][Full Text] [Related]
10. Targeting tumour-supportive cellular machineries in anticancer drug development.
Dobbelstein M; Moll U
Nat Rev Drug Discov; 2014 Mar; 13(3):179-96. PubMed ID: 24577400
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of resistance to target therapy].
Matsusaka S
Nihon Rinsho; 2012 Dec; 70(12):2195-8. PubMed ID: 23259396
[TBL] [Abstract][Full Text] [Related]
12. Exosomes and their role in tumorigenesis and anticancer drug resistance.
Milman N; Ginini L; Gil Z
Drug Resist Updat; 2019 Jul; 45():1-12. PubMed ID: 31369918
[TBL] [Abstract][Full Text] [Related]
13. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
14. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
Moretti L; Yang ES; Kim KW; Lu B
Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
[TBL] [Abstract][Full Text] [Related]
15. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
16. Targeting signalling pathways for the treatment of multiple myeloma.
Podar K; Hideshima T; Chauhan D; Anderson KC
Expert Opin Ther Targets; 2005 Apr; 9(2):359-81. PubMed ID: 15934921
[TBL] [Abstract][Full Text] [Related]
17. [Research advance on role of tumor microenvironment in mediating acquired drug resistance].
Ma XL; Xing H; Ma D
Ai Zheng; 2007 Aug; 26(8):923-6. PubMed ID: 17697561
[TBL] [Abstract][Full Text] [Related]
18. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.
Hazlehurst LA; Landowski TH; Dalton WS
Oncogene; 2003 Oct; 22(47):7396-402. PubMed ID: 14576847
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of apoptotic pathways in cancer.
Meiler J; Schuler M
Curr Drug Targets; 2006 Oct; 7(10):1361-9. PubMed ID: 17073598
[TBL] [Abstract][Full Text] [Related]
20. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
